SXSW: Luke Pustejovsky of Tactogen on novel entactogens, potential first line treatments & more... скачать в хорошем качестве

SXSW: Luke Pustejovsky of Tactogen on novel entactogens, potential first line treatments & more...

Depending on whose advice you take, investing in psychedelics might be the best or worst decision you’ll make. While the internet is awash in click bait promoting the latest celebrity promoting psychedelics, sophisticated investors are doing their homework and discovering under-the-radar opportunities before writing checks. Public or private market investing? Biotech /drug development or services businesses? Psilocybin, Ketamine, or new chemical entities ? Join some of the leading founders from the private sector and thought leaders from the space, as they share their thoughts on where the business of psychedelics is headed, what to look out for, and how to steer clear of the pitfalls. Featuring: Myriam Barthes, Journey Clinical Daniel Goldberg, Palo Santo Imran Khan, UC Berkeley Center for the Science of Psychedelics Luke Pustejovsky, Tactogen